Ironwood Pharmaceuticals (NASDAQ:IRWD) and Allergan (NYSE:AGN) report that Linzess (linaclotide) 290 mcg met its primary multi-component endpoint in a Phase IIIb study.
Ironwood rises 7.7% in after-hours trading.
Trial demonstrated linaclotide improved overall abdominal symptoms of bloating, pain and discomfort in adult irritable bowl syndrome with constipation.
Also met secondary endpoints.
Linaclotide was well-tolerated in this Phase IIIb study, with the most commonly reported adverse event being diarrhea.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.